KPIs & Operating Metrics(New)
Aesthetics Revenue By CategoryAesthetics Revenue By Category AnnualAesthetics Revenue By GeographyAesthetics Revenue By Geography AnnualBreakdown Of AssetsEmployee StatisticsEye Care Revenue By CategoryEye Care Revenue By Category AnnualEye Care Revenue By GeographyEye Care Revenue By Geography AnnualGross MarginGross Margin %Gross Margin AnnualGross Margin Annual %Hematology Oncology Revenue By CategoryHematology Oncology Revenue By Category AnnualHematology Oncology Revenue By GeographyHematology Oncology Revenue By Geography AnnualImmunology Revenue By CategoryImmunology Revenue By Category AnnualImmunology Revenue By GeographyImmunology Revenue By Geography AnnualIncome Before Income Taxes By RegionLong Lived Assets By RegionNeuroscience Revenue By CategoryNeuroscience Revenue By Category AnnualNeuroscience Revenue By GeographyNeuroscience Revenue By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX SegregationOther Key Products Revenue By CategoryOther Key Products Revenue By Category AnnualOther Key Products Revenue By GeographyOther Key Products Revenue By Geography AnnualProperty & Equipment BreakdownRevenueRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Ship To LocationRevenue By Ship To Location %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) Revenue (2016 - 2024)

AbbVie has reported Revenue over the past 14 years, most recently at $16.6 billion for Q4 2025.

  • Quarterly Revenue rose 10.04% to $16.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.2 billion through Dec 2025, up 8.57% year-over-year, with the annual reading at $61.2 billion for FY2025, 8.57% up from the prior year.
  • Revenue was $16.6 billion for Q4 2025 at AbbVie, up from $15.8 billion in the prior quarter.
  • Over five years, Revenue peaked at $16.6 billion in Q4 2025 and troughed at $12.2 billion in Q1 2023.
  • The 5-year median for Revenue is $14.4 billion (2021), against an average of $14.3 billion.
  • Year-over-year, Revenue skyrocketed 50.95% in 2021 and then fell 9.7% in 2023.
  • A 5-year view of Revenue shows it stood at $14.9 billion in 2021, then grew by 1.58% to $15.1 billion in 2022, then fell by 5.42% to $14.3 billion in 2023, then rose by 5.6% to $15.1 billion in 2024, then rose by 10.04% to $16.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Revenue are $16.6 billion (Q4 2025), $15.8 billion (Q3 2025), and $15.4 billion (Q2 2025).